Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02913495 · ClinicalTrials.gov registry record · Phase 4
Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth
A Phase 4 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 4
- Development phase
- 210
- Enrollment target
NCT02913495 is a Phase 4 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 210 participants.
The verdict
NCT02913495, a Phase 4 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 210 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the two suggested therapies for prevention of recurrent preterm birth (PTB) in women with a prior spontaneous preterm birth, vaginal and intramuscular progesterone to determine whether vaginal progesterone is superior to intramuscular progesterone in the prevention of recurrent preterm birth.
Interventions
- DRUG Vaginal Progesterone
- DRUG Intramuscular Progesterone (17 alpha hydroxprogesterone caproate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2016-09 |
| Est. Completion | 2021-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02913495
The ClinicalTrials.gov registry entry for NCT02913495 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vaginal Progesterone is the first listed.
NCT02913495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02913495 about?
NCT02913495 is a clinical study titled "Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth". The purpose of this study is to evaluate the two suggested therapies for prevention of recurrent preterm birth (PTB) in women with a prior spontaneous preterm birth, vaginal and intramuscular progesterone to determine whether vaginal progesterone is superior to intramuscular progesterone in the prev...
What is the current status of trial NCT02913495?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 210 participants. The study started on 2016-09. Estimated completion is 2021-09.
What interventions are being tested in trial NCT02913495?
The interventions under investigation include: Vaginal Progesterone (DRUG), Intramuscular Progesterone (17 alpha hydroxprogesterone caproate) (DRUG).
Who is sponsoring clinical trial NCT02913495?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.